Imugene’s Clinical Trials Show Promise and Strong Cash Position

Imugene Limited (AU:IMU) has released an update.

Imugene Limited has reported promising progress in its clinical trials, including three complete responses in its azer-cel Phase 1b trial for treating diffuse large B-cell lymphoma. The company has also received FDA Orphan Drug Designation for its VAXINIA treatment for bile tract cancer, with the first patient dosed in a Phase 1 trial in Melbourne. Imugene’s cash position stands strong at $53.3 million as of September 30, 2024.

For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.